Source comparison
CJC-1295 No DAC & Ipamorelin Protocol: Dosing Comparison
Typical Research Dose 200mcg per injection 100–200mcg per injection CJC amplifies amplitude; Ipamorelin triggers the pulse. Synergy requires both Dosing Frequency 2x daily (morning + pre-sleep) Aligns with natural circadian GH peaks at dawn and 60–90 min post-
This comparison does not assign a generated winner or score.
- Typical Research Dose
- 200mcg per injection
- 100–200mcg per injection
- CJC amplifies amplitude; Ipamorelin triggers the pulse. Synergy requires both
- Dosing Frequency
- 2x daily (morning + pre-sleep)
- Aligns with natural circadian GH peaks at dawn and 60–90 min post-sleep onset
- Half-Life
- 6–8 days
- ~2 hours
- CJC sustains baseline elevation; Ipamorelin provides acute pulsatile release
- Receptor Target
- GHRH receptor (growth hormone-releasing hormone)
- Ghrelin receptor (GHS-R1a)
- Dual-pathway stimulation prevents receptor desensitization
- Suppression Risk
- Low at ≤400mcg/day total
- Minimal at standard doses
- Pulsatile dosing (2x daily max) preserves endogenous GH rhythm
- Cycle Duration
- 8–12 weeks
- Receptor downregulation begins after 12–16 weeks. Washout required
- Professional Assessment
- CJC alone produces weak pulses without a secretagogue
- Ipamorelin alone produces short-duration spikes
- The combination mimics physiological GH release better than either peptide solo